Bafna Pharmaceuticals Ltd. engages in the manufacture of drugs and medicines of life saving drugs. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2008-06-27. The firm is primarily engaged in the business of manufacturing finished pharmaceutical formulations. The company is also involved in manufacturing 336 licensed pharmaceutical formulations and has globally registered approximately 78 of its products. Its Madhavram facility manufactures finished solid oral and liquid oral dosage forms of Betalactam and Non-Betalactam and Cephalosporin products. The company supplies its products to the United Kingdom, Europe, and Australian markets. The firm's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.